BPC-157 / TB-500 / KPV Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Confirmed high-severity market-integrity event (enforcement / recall / counterfeit)

Transparent blend · bci-1.0 · never paid-placement

Primary name

BPC-157 / TB-500 / KPV Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Synthetic 15-amino-acid gastric pentadecapeptide studied in animal models for tissue repair, angiogenesis, and GI protection.

BPC-157 has been shown in rodent and cell-culture studies to upregulate vascular endothelial growth factor receptor 2 (VEGFR2) and activate downstream Akt–eNOS signaling, promoting endothelial nitric oxide production and new vessel formation. The peptide also engages the focal adhesion kinase (FAK)–paxillin pathway, facilitating endothelial cell migration during angiogenesis. Additional preclinical data indicate modulation of nitric oxide synthesis more broadly, with context-dependent protective effects against cytotoxic NO excess while preserving physiological NO-mediated functions. These converging angiogenic and cytoprotective pathways are proposed to underlie observations of accelerated wound closure, tendon reattachment, and gastrointestinal mucosal recovery in animal injury models.

Molar mass

1419.5 g/mol

Synthetic 9-amino-acid fragment (Ac-LKKTETQ) of thymosin beta-4 studied in animal models for tissue repair, cell migration, and angiogenesis.

TB-500 binds monomeric G-actin through the same LKKT(X)E motif present in the full thymosin beta-4 protein, sequestering free actin monomers and preventing their incorporation into filamentous F-actin networks; this shifts the intracellular actin equilibrium in a manner that facilitates lamellipodia formation and directed cell migration. Concurrently, the peptide activates integrin-linked kinase (ILK) signaling, promoting downstream phosphorylation events that stimulate keratinocyte and endothelial cell motility. In rodent wound and ischemia models, these effects are accompanied by upregulation of vascular endothelial growth factor (VEGF) and accelerated capillary sprouting, suggesting a secondary pro-angiogenic axis. NF-kB pathway modulation has also been reported in preclinical inflammation models, though the mechanistic hierarchy relative to actin sequestration remains unresolved.

Molar mass

889.0 g/mol

C-terminal tripeptide of α-MSH (Lys-Pro-Val) that suppresses NF-κB-driven inflammation and is absorbed by intestinal PepT1 transporters in preclinical models.

KPV inhibits the NF-κB signaling pathway, blocking nuclear translocation of the p65 subunit and reducing downstream transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Unlike the full α-MSH molecule, KPV's anti-inflammatory activity appears to be partially independent of classical melanocortin receptor engagement, suggesting intracellular or alternative receptor mechanisms that remain under investigation. In intestinal epithelia, KPV is actively transported into cells via the proton-coupled oligopeptide transporter PepT1 (SLC15A1), which is upregulated in inflamed colonic mucosa, potentially creating preferential delivery to inflamed sites. Additional activity in keratinocytes and macrophages involves suppression of MAP-kinase signaling cascades alongside NF-κB, consistent with broad attenuation of innate immune activation.

Molar mass

192.21 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Subcutaneous (SC) is the most commonly reported research route across BPC-157, TB-500, and KPV in the animal and preclinical literature.

Most common research route for BPC-157, TB-500, and KPV in animal models (rats, mice, dogs); systemic delivery studied for musculoskeletal, gut, and neurological endpoints

Bioavailability: BPC-157 IM half-life ~30 min in rats; IV half-life ~15.2 min (rats) and ~5.27 min (beagle dogs); human PK not established. TB-500 plasma half-life estimated <30 min by doping-control analyses with prolonged tissue-level effects attributed to intracellular accumulation.

Subcutaneous injection is the dominant research route across all three components; no peer-reviewed human clinical trial data exists for BPC-157, and human PK is not established for any component.

Studied in animal models (rats) for BPC-157; reported for TB-500 in some research protocols

Bioavailability: BPC-157 IM half-life ~30 min in rats (vs ~15.2 min IV); used for deeper tissue access near injury site in animal studies.

IM route studied in animals for localized tissue exposure; no human PK data.

BPC-157 IV pharmacokinetics characterized in rats and beagle dogs

Bioavailability: BPC-157 IV half-life ~15.2 min (rats) and 5.27 ± 2.25 min (beagle dogs); human IV data not established.

IV route used in animal PK studies only; not a typical research-use route for the blend.

Thymosin beta-4 (TB-500 parent) administered intraperitoneally in rat full-thickness wound model (Malinda et al., 1999)

Bioavailability: IP Tβ4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days post-wounding vs saline controls in rats.

IP route documented for thymosin beta-4 in rodent wound-healing studies; not commonly used in blend research protocols.

BPC-157 oral administration studied in animal models (gut protection, NSAID-induced damage); KPV oral administration studied in colitis animal models

Bioavailability: BPC-157 reported stable in human gastric juice for over 24 hours (Sikiric et al.), attributed to high proline content (26.7%) conferring proteolytic resistance. KPV oral bioavailability is lower than injectable forms for systemic applications; KPV is susceptible to enzymatic degradation and rapid elimination, motivating glycoalkylated analog research (Songok et al., 2018). TB-500 oral route not well characterized in primary literature.

Oral stability ≠ oral absorption; BPC-157 gastric stability is a chemical-stability observation, not a validated human bioavailability figure. KPV oral delivery is challenging owing to enzymatic degradation.

Thymosin beta-4 applied topically in rat full-thickness wound model (Malinda et al., 1999); BPC-157 topical application studied in animal wound models; KPV topical delivery researched but limited by hydrophilicity

Bioavailability: Topical Tβ4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days in rats. KPV is extremely hydrophilic, making transdermal delivery challenging.

Topical route documented for TB-500 parent (Tβ4) and BPC-157 in animal wound models; KPV topical delivery limited by hydrophilicity and enzymatic lability.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $5.09 · median $5.09 · p75 $5.09 · 4 researched vendors

Legit, COA-backed band: $4.00–$8.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$51

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Independent aggregate testing (Finnrick Analytics, 666 BPC-157 samples from 98 vendors, Dec 2024–Jun 2026) reports purity typically ranging 96.76%–99.95% (5th–95th percentile); vendor-published Janoshik HPLC COAs for BPC-157/TB-500 blends commonly claim ≥99% per peptide.

Independent labs cited for this compound

No FDA-initiated Class I/II recall specific to a BPC-157/TB-500/KPV blend product was found in FDA recall databases. Enforcement has taken the form of warning letters, import alerts, warehouse raids, and criminal forfeitures rather than product recalls, consistent with these peptides lacking FDA-approved drug applications.

Buyer red-flag checklist

• Single combined COA without per-peptide HPLC and mass spec for BPC-157 (1,419.5 Da) and TB-500 (4,963 Da)
• Only in-house testing with no third-party verification
• Prices below $3/mg total — likely substituted TB-4 fragment (residues 17-23) for full TB-500 (43 residues)
• No mass spectrometry at all
• Vague 'BPC/TB' labeling without confirming whether full TB-500 or a TB-4 fragment is shipping
• Cryptocurrency-only payment and no return/reship policy
• Falsified CoA records documented at foreign API manufacturers under Import Alert 66-40
• Lead contamination in BPC-157 vials and endotoxins in TB-500 vials documented in independent testing (New Yorker/SwissChems, 2026)
• KPV component rarely tested separately in blend COAs — three-component blends require three independent identity/purity confirmations

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: Finnrick Analytics' BPC-157 test history (200 displayed tests) shows 136 pass / 64 fail (~32% fail rate); quantity diverges by up to ±71% vs advertised value at the 95th percentile. The New Yorker (Apr 2026) documented a SwissChems CJC-1295 vial at <42% of advertised dose. Note: figures are for BPC-157 component only; blend-specific (TB-500, KPV) aggregate underdosing data is not separately published.

• Detention Without Physical Examination of bulk pharmaceutical active ingredients manufactured outside the U.S. with CGMP violations. Expanded May 2026 to add 38 foreign peptide API manufacturers (China/India/South Korea) covering ~30% of injectable peptide API supply; inspectors found falsified CoA records, sterility failures, and heavy-metal testing deficiencies.66-40
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Neither BPC-157, TB-500, nor KPV is named on a blend-specific WADA schedule. Per component: BPC-157 is prohibited at all times, in- and out-of-competition, under Section S0 (Non-Approved Substances). TB-500 (thymosin beta-4) is also prohibited under S0 — anti-doping compliance trackers place it under the 'Growth Factors and Growth Factor Modulators' heading within S0, NOT under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics specifically enumerates GH secretagogues/GHRP/GHRH/EPO-class substances there, which TB-500 is not). Corrected from an earlier confident 'TB-500 is S2-prohibited' framing, which an independent check found to be a common vendor-blog mischaracterization. KPV could not be confirmed as specifically named on any primary WADA document checked this pass; its S0 status here is an inference from the general non-approved-substance catch-all, not a confirmed named listing.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-reported anecdotal experiences; no controlled human trials for the blend
• Vendor-affiliated / affiliate-linked content present on aggregator blogs
• Selection bias toward positive reports in enthusiast communities
• Wide dosing and protocol variability across self-reporters

Manually researched from reddit— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet